Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Urogenital Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Multiple Myeloma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Genital Neoplasms, Male 1Dendritic Cell Sarcoma, Interdigitating 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Arthritis, Rheumatoid 1

Interventions

Prednisone 103enzalutamide 76Docetaxel 72Abiraterone Acetate 68Leuprolide 47acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45abiraterone 39apalutamide 29Prednisolone 27bicalutamide 26Zoledronic Acid 24radium Ra 223 dichloride 22pembrolizumab 22darolutamide 22Goserelin 22Triptorelin Pamoate 17cabazitaxel 16Androgen Antagonists 15sipuleucel-T 13luprolide acetate gel depot 12Injections 12Dexamethasone 12olaparib 11gallium 68 PSMA-11 10Mitoxantrone 10Pluvicto 9Ipilimumab 9Dutasteride 9Cyclophosphamide 9relugolix 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Prostatic Neoplasms × Adrenal Cortex Hormones × Clear all
NCT06925737 2026-05-29

MK-2400-001

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,440 enrolled
Genitourinary

Prostatic Neoplasms

NCT05067140 2026-05-05

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

Novartis

Phase 1/2 Active not recruiting
152 enrolled
Genitourinary

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡